AI in Proteomics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The aI in proteomics market is expected to grow from USD 5.98 billion in 2025 to USD 6.72 billion in 2026 and is forecasted to reach USD 12.51 billion by 2031 at 13.22% CAGR over 2026-2031. This report is Segmented by Component (Software, Services), Technology (Mass Spectrometry, Protein Microarrays, and Others), Application (Biomarker Discovery, Drug Discovery and Development, Others), End-User (Pharmaceutical and Biotechnology Companies, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global AI In Proteomics Market Trends and Insights

Rising Demand for Precision Medicine and Translational Biomarkers

Population-scale biobanking has changed the economics of biomarker work in the AI in proteomics market because large cohorts now provide the training depth needed for stronger model development and validation. Studies built on cohorts ranging from 5,000 to 50,000 samples, including work linked to UK Biobank and FinnGen, show that broader and deeper proteomic datasets can support clinically relevant biomarker panel development at a pace that was harder to achieve a few years earlier.Thermo Fisher Scientific’s collaboration with Precision Health Research Singapore for the PRECISE-SG100K initiative extends the same pattern into Asia through 10,000 plasma samples profiled with complementary Olink assay and Orbitrap mass spectrometry workflows.This matters for the AI in proteomics market because validated panels are moving beyond research publication cycles and into companion diagnostic and regulated clinical development programs. That shift expands commercial demand from one-time discovery projects toward repeat software usage, model refinement, and workflow monitoring across study stages. As the AI in proteomics market moves closer to clinical deployment, vendors with stronger biomarker interpretation tools and cleaner audit trails are positioned to capture a larger share of recurring spending.

AI-Enabled Deconvolution of High-Dimensional Proteomics Data

The AI in proteomics market continues to face a core data challenge because model performance depends on the quality, structure, and interoperability of the underlying proteomics datasets as much as on the model itself. A 2026 Proteomes commentary argued that AI readiness should begin at the point of data capture, and it also noted that proteoform-resolved inputs can outperform broader protein-group approaches in pathway inference and cross-cohort generalization. In the AI in proteomics market, this kind of tool matters because database-independent interpretation helps researchers work with poorly annotated organisms, rare disease states, and complex immunopeptidomics samples. Neural network-based spectral prediction is also lowering the effort required to build high-quality reference libraries, which can shorten setup times for new programs. As a result, the AI in proteomics market is seeing more value move toward software environments that can standardize raw input quality and improve confidence in downstream biological interpretation.

High Cost of Multimodal Instrumentation and Compute Infrastructure

The AI in proteomics market still faces a meaningful adoption barrier because next-generation mass spectrometry systems, supporting compute layers, and managed data infrastructure require large capital commitments. Single-cell proteomics and spatial proteoform analysis depend on high-specification instrumentation, and the combined cost of instruments, compute, and data handling can exceed the annual proteomics budgets of many hospitals and academic centers outside North America and Western Europe. That cost issue matters in the AI in proteomics market because growth assumptions rely on broader geographic participation, including countries where research budgets and procurement flexibility are more limited. Leasing models and cloud-based laboratory service structures reduce some of the upfront burden, but they do not yet remove the full cost gap for end-to-end AI proteomics workflows. The region with the fastest projected growth, Asia-Pacific, still reflects strong public investment ambition rather than a fully balanced cost structure today. Until the total deployment cost falls further, the AI in proteomics market will remain more accessible to well-funded biopharma groups, national programs, and top research centers than to mid-tier institutions.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Single-Cell and Spatial Proteomics Workflows
• Rising Demand for Automated Drug Discovery Target Validation
• Lack of Cross-Platform Data Standardization for AI Model Training

Segment Analysis

Software held 60.37% of AI in proteomics market share in 2025, which shows that value creation has moved toward interpretation, workflow orchestration, and decision support rather than remaining centered on hardware alone. In the AI in proteomics market, this revenue mix reflects a clear change in buying priorities because researchers and biopharma teams need tools that can turn large proteomic datasets into usable outputs across discovery and translational programs. Regional specialists are also gaining room to compete, and aiwell Japan’s integrated proteomics analytics platform shows how unified interfaces for mass spectrometry, affinity assays, and pathway analysis can answer customer demand that larger OEMs have not fully addressed. This makes the software layer the most defensible category in the AI in proteomics market because it shapes daily workflow use, data portability, and customer switching costs.

The AI in proteomics market for services is projected to expand at a 13.49% CAGR from 2026 to 2031, which shows how strongly customers are leaning toward outsourced and outcome-based operating models. Pharmaceutical teams increasingly want support that runs from sample preparation through AI-assisted interpretation, because this can shorten early-stage project timelines without requiring internal platform buildout. Over time, the AI in proteomics market is likely to see a wider mix of hybrid models where software subscriptions, managed analytics, and project-based scientific support are sold together rather than as separate offers.

Mass spectrometry accounted for 41.83% of revenue in 2025, and that lead remains central to the AI in proteomics market because no competing platform offers the same combination of proteome depth, post-translational modification visibility, and broad discovery utility. The technology remains the reference layer for discovery-heavy programs, especially where researchers need to quantify thousands of proteins in parallel and retain detailed molecular resolution

The AI in proteomics market for next-generation sequencing is projected to expand at a 13.76% CAGR from 2026 to 2031, driven by closer operational convergence between proteomics and genomics. Illumina’s completed acquisition of SomaLogic in January 2026 created an NGS-based proteomics platform that can measure up to 11,000 proteins using aptamer sequencing on standard NovaSeq infrastructure. That move matters in the AI in proteomics market because it overlays proteomic measurement on existing sequencing workflows and can improve cost efficiency at high sample volumes. It also gives multiomics programs a more unified instrument layer, which is attractive for population studies and large translational datasets. Protein microarrays, chromatography, X-ray crystallography, and microfluidics continue to hold defined niche roles, and microfluidics is gaining more attention as smaller-format proteomics workflows move closer to point-of-care and constrained-sample use cases.

Complete Report Scope:

• By Component
  • Software
  • Services
• By Technology
  • Mass Spectrometry
  • Protein Microarrays
  • Chromatography
  • Next-Generation Sequencing
  • X-Ray Crystallography
  • Microfluidics
  • Other Technologies
• By Application
  • Biomarker Discovery
  • Drug Discovery and Development
  • Clinical Diagnostics
  • Precision and Personalized Medicine
  • Agricultural and Environmental Proteomics
  • Other Applications
• By End-User
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Contract Research Organizations
  • Other End-Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 50.14% of AI in proteomics market share in 2025, which kept it as the leading regional contributor because it combines major biopharma headquarters, academic medical centers, and established AI software ecosystems in one dense operating environment. The region also benefits from clearer regulatory direction, because evolving FDA Software as a Medical Device guidance gives pharmaceutical users a more structured route for integrating software outputs into regulated development workflows. Europe remained the second-largest region because Horizon Europe funding, a dense pharmaceutical base, and GDPR-driven interest in on-premise and federated deployments continue to support local demand patterns.

Asia-Pacific is projected to grow at a 16.34% CAGR from 2026 to 2031, which makes it the fastest-growing regional block in the AI in proteomics market because government biobanking, domestic AI investment, and contract research expansion are moving in parallel. The region’s growth pattern differs from North America because it relies more visibly on coordinated national initiatives and infrastructure-building programs. China’s National Supercomputer Center in Tianjin launched the GalaxyVS AI platform in May 2026, using the DrugCLIP deep learning framework from Tsinghua University to enable virtual screening of 100 billion synthesizable compounds in support of faster target validation pipelines. Singapore’s PRECISE-SG100K collaboration is also important because it is building a large and ethnically diverse plasma proteome reference set that can improve biomarker model relevance for Asian populations. As the AI in proteomics market expands in Asia-Pacific, buyers are likely to put increasing weight on local data control, regional deployment options, and scalable partnerships with CROs and academic networks.

Middle East and Africa remains an early-stage part of the AI in proteomics market, but sovereign health investments tied to precision medicine programs are creating an initial base for proteomics infrastructure and analytics demand. South America is still constrained by high instrument import costs and limited domestic proteomics talent, even though university groups in Brazil and Argentina continue to support active research linked to oncology biomarker programs. Both regions are growing from a low base in the AI in proteomics market, and their progress depends more heavily on cloud-native delivery models that can reduce upfront capital needs. This pattern suggests that platform familiarity and skills development may arrive before large-scale laboratory buildout, which is similar to how other advanced life science workflows spread into these regions over earlier adoption cycles.

List of Companies Covered in this Report:

• Agilent Technologies
• Bio-Rad Laboratories
• Bio-Techne
• Bruker
• Creative Proteomics
• Danaher
• GE HealthCare Technologies Inc.
• Illumina
• Merck
• Olink Holding AB
• Oxford Nanopore Technologies plc
• Promega
• Proteome Sciences plc
• QIAGEN
• Revvity, Inc.
• Seer, Inc.
• Shimadzu
• SomaLogic, Inc.
• Thermo Fisher Scientific
• Waters Corporation

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support